Average common and common equivalent shares - diluted (in thousands)
38,055
37,500
37,326
37,231
37,005
Balance Sheet Data as of June 30:
2018
2017
2016
2015
2014
Cash, cash equivalents and short-term available-for-sale investments
181,754
$
157,714
$
95,835
$
110,921
$
363,354
Working capital
318,856
212,503
199,744
208,515
443,022
Total assets
1,593,202
1,558,219
1,129,581
1,063,360
862,491
Total shareholders' equity
1,079,061
949,627
879,280
846,935
795,265
Cash Flow Data:
2018
2017
2016
2015
2014
Net cash provided by operating activities
$
170,367
$
143,721
$
144,157
$
139,359
$
136,762
Capital expenditures
20,934
15,179
16,898
19,905
13,821
Cash dividends declared per share
1.28
1.28
1.28
1.27
1.23
Employee Data as of June 30:
2018
2017
2016
2015
2014
Employees
1,943
1,789
1,560
1,356
967
(1)
The Company acquired Trevigen on September 5, 2017, Atlanta Biologicals on January 2, 2018, and Eurocell Diagnostics on February 1, 2018.
(2)
The Company acquired Space on July 1, 2016, and Advanced Cell Diagnostics on August 1, 2016.
(3)
The Company acquired Cliniqa on July 8, 2015, and Zephyrus on March 21, 2016.
(4)
The Company acquired Novus Biologicals on July 2, 2014, ProteinSimple on July 31, 2014, and CyVek on November 3, 2014.
(5)
The Company acquired Bionostics on July 22, 2013, and PrimeGene on April 30, 2014.
(6)
Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2018 - $74.2 million; 2017 - $73.2 million; 2016 - $37.6 million; 2015 - $37.6 million; 2014 - $20.0 million.
filings.tools